Brokerages Set Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Target Price at $9.71

Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been assigned a consensus recommendation of "Buy" from the nine research firms that are covering the firm, Marketbeat reports. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 month target price among analysts that have updated their coverage on the stock in the last year is $9.71.

Several research analysts recently weighed in on ACRS shares. HC Wainwright restated a "buy" rating and set a $16.00 price target (down from $20.00) on shares of Aclaris Therapeutics in a report on Wednesday, May 14th. Cantor Fitzgerald started coverage on shares of Aclaris Therapeutics in a report on Tuesday, March 18th. They set an "overweight" rating on the stock. Wedbush started coverage on shares of Aclaris Therapeutics in a report on Wednesday, May 28th. They set an "outperform" rating and a $8.00 price target on the stock. Finally, Scotiabank cut their price target on shares of Aclaris Therapeutics from $15.00 to $9.00 and set a "sector outperform" rating on the stock in a report on Friday, May 9th.

Institutional Trading of Aclaris Therapeutics

Several hedge funds have recently added to or reduced their stakes in ACRS. ExodusPoint Capital Management LP bought a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $26,000. Invesco Ltd. bought a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $28,000. Graham Capital Management L.P. bought a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $35,000. Commonwealth Equity Services LLC bought a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $36,000. Finally, Alpine Global Management LLC bought a new stake in shares of Aclaris Therapeutics in the fourth quarter valued at approximately $38,000. Institutional investors own 98.34% of the company's stock.

Aclaris Therapeutics Stock Down 3.9%

ACRS traded down $0.06 during midday trading on Thursday, hitting $1.47. The company had a trading volume of 469,573 shares, compared to its average volume of 1,197,918. The company has a market capitalization of $159.17 million, a price-to-earnings ratio of -2.83 and a beta of 0.41. The stock's 50 day moving average price is $1.31 and its 200 day moving average price is $2.02. Aclaris Therapeutics has a 52 week low of $1.05 and a 52 week high of $5.17.

Aclaris Therapeutics (NASDAQ:ACRS - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.07. Aclaris Therapeutics had a negative net margin of 136.65% and a negative return on equity of 40.26%. Research analysts predict that Aclaris Therapeutics will post -0.82 EPS for the current year.

Aclaris Therapeutics Company Profile

Aclaris Therapeutics, Inc a clinical-stage biopharmaceutical company, engages in the development of novel drug candidates for immune-inflammatory diseases in the United States. The company operates through two segments, Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing therapies to address significant unmet needs for immuno-inflammatory diseases.